TrialDiabetes, obesity & metabolism2022

Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.

What the trial testedas reported · 382 people · 2022

Not counted

2.1×1.2× to 3.4×

Bigger than 5 in 10 for glycemic control

As reported

OR 2.1, 95% CI 1.23–3.42

the abstract, start to end

… response (HbA1c <53 mmol/mol; odds ratio 2.1, 95% CI 1.23-3.42; P = 0.006).

← favours treatmentfavours comparator →

could be chance

Glycemic control

OR 2.11.23–3.42

MetforminSGLT2 inhibitorsDPP-4 inhibitorsSulfonylureas & glinidesGlycemic control

1 / 3

2022

2023

2024

2025

this paperpooled ittrialcites it